Global Veterinary Vaccine Market Overview:
Vaccines employed for the prevention of several diseases that affect animals can be grouped under veterinary vaccines. These vaccines are an important arrow in the quiver of the veterinarian and are arguably one of the most powerful tools in keeping animals healthy and well. They also have an impact on human health by ensuring safe food supplies and preventing animal-to-human transmission of infectious diseases. Also, these vaccines be an efficient tool in reducing the need to use antibiotics in animals, thereby contributing to the fight against antimicrobial resistance. Recent advances in technologies and improved understanding of pathogenicity, immunology, and epidemiology have opened new opportunities for preventing infectious diseases at an unprecedented level. According to AMA, the Global Veterinary Vaccine market is expected to see growth rate of 5.9%
- Increasing Incidence of Livestock Diseases
- Increasing Incidence of Zoonotic Diseases
- Initiatives by Government Agencies and Animal Associations
- High Storage Costs for Vaccines
- Shortage of Veterinarians and Skilled Farm Workers
- Recent Advancements in Technologies
- Improved Understanding of Pathogenicity, Immunology and Epidemiology Have Opened New Opportunities
- Infectious & Bacterial Diseases Remain a Major Challenge
Some of the key players profiled in the report are Zoetis Animal Healthcare (United States), Merck & Co. (United States), Virbac SA (France), Hester Biosciences Ltd (India), Elanco (United States), Boehringer Ingelheim Animal Health GmbH (Germany), Ceva Sante Animale (France), Phibro Animal Health Corp. (United States), HIPRA (Spain) and MVP Laboratories Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like QianYuanHao Biological Corporation Limited (China), IZO S.r.l. (Italy), Intervet International BV (Netherlands) and Indian Immunologicals Limited (India). Analyst at AdvanceMarketAnalytics see United States Vendors to retain maximum share of Global Veterinary Vaccine market by 2024. Considering Market by Technology, the sub-segment i.e. Live Attenuated Vaccines will boost the Veterinary Vaccine market.
On 17 May 2019, Ceva Santé Animale (“Ceva”) and IDT Biologika GmbH have reached a provisional agreement for Ceva to acquire IDT’s veterinary biopharmaceutical portfolio and R&D activities, allowing IDT to focus on the manufacture of human biotechnology vaccines and pharmaceuticals for national and international markets. and On 26 April 2019, Elanco Animal Health has announced it has signed an agreement to acquire Aratana Therapeutics, a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant. Elanco has also signed a development and commercialization agreement with VetDC for Tanovea-CA1, the first U.S. Food and Drug Administration (FDA) conditionally approved canine lymphoma treatment.
On 24 Jan. 2019, Boehringer Ingelheim, the world’s leading animal health company, announced that swine vaccine Ingelvac®PRRS MLV, produced by its veterinary vaccine manufacturing plant in the China Medical City in Taizhou, Jiangsu Province, is now officially supplied to the China market. Shifting imported vaccines to locally-produced vaccines will help significantly shorten the interval between the plant and animal farms. and On 12 Oct. 2018 – Boehringer Ingelheim has inaugurated its new global center for biological research and development at its Lyon Porte-des-Alpes (LPA) location in Saint-Priest France. With this 70 million euro investment, the German group signals its intention to reinforce its leading position in the veterinary vaccine market by bringing its R&D and biological production activities into the same center of excellence.
APHIS regulates veterinary biologics (vaccines, bacterins, antisera, diagnostic kits, and other products of biological origin) to ensure that the veterinary biologics available for the diagnosis, prevention, and treatment of animal diseases are pure, safe, potent, and effective. This work is done by APHIS Center for Veterinary Biologics (CVB) and is centered around enforcement of the Virus Serum Toxin Act.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Veterinary Vaccine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Veterinary Vaccine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Veterinary Vaccine Manufacturers, Veterinary Vaccine Raw Material Suppliers, Veterinary Vaccine Traders/Distributors, Veterinary Vaccine Importer/Exporter, Technology Investors, Government Research Institutes and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.